- AbbVie Inc (NYSE:ABBV) has ended a research partnership with Sweden's BioArctic, backing out further development of an experimental Parkinson's disease drug and other related medicines.
- A clinicaltrials.gov listing for ABBV-0805 says a Phase I study is "Withdrawn (Strategic considerations)."
- The partnership between AbbVie and BioArctic, which began in 2016, was focused on antibody drugs targeting alpha-synuclein. This protein can misfold and accumulate abnormally in the brains of patients with Parkinson's and related dementias.
- In 2019, a Phase 1 study of the lead asset, ABBV-0805, was initiated. The results from the study, presented at the International Congress of Parkinson's Disease and Movement Disorders in September 2021, support a continuation into Phase 2 with once-monthly dosing.
- "We are disappointed that AbbVie has taken this decision," CEO Gunilla Osswald said in a prepared statement. "All available data indicates that ABBV-0805 has uniquely high selectivity for the pathological forms of aggregated alpha-synuclein and Phase 1 data supporting progression to Phase 2."
- AbbVie terminated its Parkinson's disease agreement with Voyager Therapeutics Inc (VYGR) in August 2020, which focused on alpha synuclein-focused vectorized antibodies.
- Price Action: ABBV shares are up 0.74% at $157.51 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
AbbVie Walks Away From Parkinson's Drug Pact With BioArctic
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks